FIELD: chemistry.
SUBSTANCE: invention relates to a novel compound of formula (1) and a pharmaceutically acceptable salt thereof. Disclosed is a medicament containing a compound represented by general formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof. Compounds have the properties of the activation effect of soluble guanylate cyclase (sGC) and can be used to treat diseases such as heart failure, hypertension, pulmonary hypertension and coronary heart disease. In formula (1)
Ar represents a phenyl group or a 5-membered heteroaryl group containing a sulphur atom; Y represents a hydrogen atom, C1-C6 alkyl group, halogen C1-C4 alkyl group, a cyano group or a halogen atom; A represents a C1-C3 alkylene chain which may be substituted wit two C1-C2 alkyl groups, where are two C1-C2 alkyl groups may be substituents on the same carbon atom of the C1-C3 alkylene chain and also two C1-C2 alkyl groups taken together can form a C3-C5 saturated hydrocarbon ring containing one carbon atom of the C1-C3 alkylene chain; X represents a hydrogen atom or a halogen atom; V represents an oxygen atom or a methylene chain; R is a group selected from the following formulae
,
where R1, R2 and R3 each independently represents a hydrogen atom, a halogen atom, C1-C6 alkyl group that may have a substitute C3-C6 cycloalkyl group, C1-C6 alkoxy, C3-C6 cycloalkyl group, C3-C6 cycloalkoxy, halogen C1-C4 alkyl group, a phenyl group which may have a substituent group on the phenyl ring, a phenoxy group which may have a substituent group on the phenyl ring, where the substituent group is a halogen atom, cyano group or C1-C6 alkyl group, a benzyl group that may have a substituent group on the benzene ring, a phenethyl group which may have a substituent group on the benzene ring, or a benzyloxy group which may have a substituent group on the benzene ring, where the substituent group is a halogen atom or halogen C1-C6 alkyl group; W represents =CH- or a nitrogen atom, n is an integer from 1 to 3, and if n is 2 or more, the values of n for R1 may differ from each other.
EFFECT: disclosed are 4-aminomethylbenzoic acid derivatives.
8 cl, 61 tbl, 60 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BICYCLIC COMPOUND | 2013 |
|
RU2640416C2 |
| BENZOPYRAN DERIVATIVE | 2005 |
|
RU2366658C2 |
| SPIROKETAL DERIVATIVES AND USE THEREOF AS MEDICINAL AGENT AGAINST DIABETES | 2006 |
|
RU2416617C2 |
| SULPHONAMIDE COMPOUND OR SALT THEREOF | 2017 |
|
RU2732572C2 |
| NEW TETRAHYDROPYRIMIDINE CONNECTION OR ITS SALT | 2015 |
|
RU2636310C1 |
| TRICYCLIC COMPOUNDS OF BENZOPYRAN AS ANTIARRHYTHMIC AGENTS | 2005 |
|
RU2380370C2 |
| CYNNAMIDE COMPOUND | 2005 |
|
RU2361872C2 |
| MORPHOLINOPURINE DERIVATIVES, HAVING PI3K AND/OR mTOR INHIBITING ACTIVITY | 2009 |
|
RU2490269C2 |
| TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | 2012 |
|
RU2632870C2 |
| BENZOPYRROLE DERIVATIVES CONTAINING HEXAHYDROPYRIDINE CYCLE | 2005 |
|
RU2332413C1 |
